INT227772

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.29
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 11
Total Number 12
Disease Relevance 7.85
Pain Relevance 2.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
CD86 3
T cells 3
macrophages 1
B cells 1
dendritic cells 1
Cd80 (Mus musculus)
Pain Link Frequency Relevance Heat
abatacept 206 99.96 Very High Very High Very High
Arthritis 103 98.44 Very High Very High Very High
rheumatoid arthritis 185 88.60 High High
Infliximab 2 88.40 High High
Potency 2 86.44 High High
cytokine 38 81.64 Quite High
Inflammation 9 74.80 Quite High
tolerance 32 74.48 Quite High
Multiple sclerosis 5 47.64 Quite Low
cva 8 45.32 Quite Low
Disease Link Frequency Relevance Heat
Arthritis 50 98.44 Very High Very High Very High
Apoptosis 12 97.08 Very High Very High Very High
Lymphatic System Cancer 164 94.72 High High
Immunization 32 93.84 High High
Chronic Lymphoid Leukemia 28 89.32 High High
Experimental Arthritis 55 89.04 High High
Rheumatoid Arthritis 185 88.60 High High
Ankylosis 5 87.40 High High
Disease 222 85.64 High High
Arthropathy 7 75.92 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The same researchers also demonstrated that CTLA4Ig, an immunoglobulin shown to block the interaction of CD80 and CD86 ligands on antigen-presenting cells with CTLA4 receptors on T-cells, appeared to stabilize the expression of adenovirus in the TM [8].
CD80 Binding (interaction) of in T-cells
1) Confidence 0.29 Published 2008 Journal Molecular Vision Section Body Doc Link PMC2267727 Disease Relevance 0.11 Pain Relevance 0
Ligands for ICOS are constitutively expressed on APCs and, in contrast to CD80 and CD86, do not underlie the control of CD40 or signals involving the NF-?
CD80 Binding (contrast) of in CD86
2) Confidence 0.19 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2582810 Disease Relevance 0.33 Pain Relevance 0.08
In addition to the CD80/86-CD28 interaction, co-stimulation of T cell responses occurs through the CD40-CD154 interaction between APCs and T cells.
CD80 Binding (interaction) of in T cell
3) Confidence 0.19 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875641 Disease Relevance 1.00 Pain Relevance 0.49
These patients have shown some improvement following treatment with Abatacept, a clinically approved CTLA4-Ig, which is believed to inhibit antigen presenting cell (APC) co-stimulation of T cells by high affinity binding to CD80/86 [3].
CD80 Binding (binding) of in T cells associated with abatacept
4) Confidence 0.19 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875641 Disease Relevance 0.82 Pain Relevance 0.44
The best way to inhibit CD28-CD80/CD86 interaction is by means of cytotoxic T-lymphocyte antigen (CTLA)4-immunoglobulin (Ig).
CD80 Binding (interaction) of in CD86
5) Confidence 0.18 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2582810 Disease Relevance 0.13 Pain Relevance 0.13
Antibodies targeting CD19, CD20, CD22, in combination with a toxin, CD23, CD40, CD80, and HLA-DR are being evaluated in clinical trials, and their additional benefit will be evaluated in coming years (DiJoseph et al 2004, 2006; Byrd et al 2005; Czuczman et al 2005; Foreno-Torres et al 2006).
CD80 Binding (combination) of
6) Confidence 0.16 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727901 Disease Relevance 1.20 Pain Relevance 0
Antibodies targeting CD19, CD20, CD22, in combination with a toxin, CD23, CD40, CD80, and HLA-DR are being evaluated in clinical trials, and their additional benefit will be evaluated in coming years (DiJoseph et al 2004, 2006; Byrd et al 2005; Czuczman et al 2005; Foreno-Torres et al 2006).
CD80 Binding (targeting) of
7) Confidence 0.16 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727901 Disease Relevance 1.22 Pain Relevance 0
These observations suggest that CD28–CD80/86 interactions are important in the initiation of the arthritis.
CD80 Binding (interactions) of associated with arthritis
8) Confidence 0.14 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833980 Disease Relevance 1.34 Pain Relevance 0.44
One of these fusion proteins, abatacept, binds CD80 more avidly than CD86.
CD80 Binding (binds) of in CD86 associated with abatacept
9) Confidence 0.14 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833980 Disease Relevance 0.36 Pain Relevance 0.29
CD28 is present on most T cells and it binds to both CD80 (B7-1) and CD86 (B7-2), which are present on antigen-presenting cells, including dendritic cells, B cells, and macrophages.
CD80 Binding (binds) of in dendritic cells
10) Confidence 0.14 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833980 Disease Relevance 0.45 Pain Relevance 0.11
CD28 is present on most T cells and it binds to both CD80 (B7-1) and CD86 (B7-2), which are present on antigen-presenting cells, including dendritic cells, B cells, and macrophages.
CD80 Binding (binds) of in macrophages
11) Confidence 0.05 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833980 Disease Relevance 0.45 Pain Relevance 0.11
CD28 is present on most T cells and it binds to both CD80 (B7-1) and CD86 (B7-2), which are present on antigen-presenting cells, including dendritic cells, B cells, and macrophages.
CD80 Binding (binds) of in B cells
12) Confidence 0.05 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833980 Disease Relevance 0.45 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox